MitoTam results in stronger activation of the apoptotic pathway in MCF7 Her2high cells compared with mock MCF7 cells[1].

MitoTam (intraperitoneal injection; 0.25?μmol/mouse; twice a week; 2 weeks) slows down the growth of MCF7 mock tumors and stops tumor progression after two doses; suppresses Her2high carcinomas decreased threefold from the original size with complete disappearance[1].